Skip to main content

Table 1 Baseline characteristics

From: Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study

 

FCM (n = 13)

FDI (n = 13)

p value

Demographics

 Age [years]

40 ± 10

34 ± 11

0.166

 Caucasians, n [%]

13 (100)

13 (100)

 

 eGFRCrea (CKD-EPI) [mL/min/1.73 m2]

102 ± 11

101 ± 21

0.951

 BMI [kg/m2]

26 ± 6

23 ± 2

0.140

 Diabetes mellitus, n [%]

1 (7.7)

0 (0)

0.308

Vital signs

 BP systolic [mmHg]

124 ± 10

114 ± 10

0.022

 BP diastolic [mmHg]

79 ± 8

74 ± 10

0.217

 Heart rate [BPM]

71 ± 12

69 ± 12

0.667

Iron deficiency parameters

 Previous intravenous iron therapy, n [%]

6 (46.2)

5 (38.5)

0.691

 Hemoglobin [g/dL]

10.1 ± 1.4

10.7 ± 1.2

0.273

 Transferrin [mg/dL]

344 ± 37

325 ± 34

0.186

 Transferrin saturation [%]

4 [3; 7]

5 [4; 7]

0.644

 Ferritin [ng/mL]

6 [4; 8]

8 [6; 12]

0.193

 Hepcidin [ng/mL]

0.9 [0.4; 1.4]

0.6 [0.1; 1.1]

0.469

Mineral metabolism parameters

 Plasma phosphorus [mg/dL]

3.2 ± 0.4

3.6 ± 0.6

0.101

 FePi [%]

12 ± 6

14 ± 9

0.417

 Plasma intact FGF23 [pg/mL]

49 [42; 60]

47 [40; 58]

0.387

 Plasma c-terminal FGF23 [RU/mL]

385 [199; 998]

451 [190; 840]

0.911

 Serum calcium [mmol/L]

2.3 ± 0.1

2.3 ± 0.1

1.000

 Serum parathormone [pg/mL]

40 [37; 55]

40 [33; 52]

0.253

 Serum 1.25-dihydroxyvitamin D [ng/L]

55 ± 15

51 ± 15

0.378

 Serum 25-hydroxyvitamin D3 [ng/mL]

19 [10; 22]

24 [21; 29]

0.026

 Alkaline phosphatase [U/L]

74 [52; 82]

48 [41; 91]

0.724

 Serum prokollagen type 1 N propeptide [μg/L]

51 [32; 63]

57 [40; 74]

0.305

 Urinary pyridinoline [μg/g creatinine]

176 [138; 187]

176 [153; 236]

0.183

 Urinary desoxypyridinoline [μg/g creatinine]

36 [31; 42]

46 [27; 58]

0.303

Clinical safety parameters

 LVMI [g/m2]

69 ± 13

67 ± 10

0.693

 LAVI [mL/m2]

42 ± 10

38 ± 6

0.308

 E/e’

6.9 ± 1.5

6.0 ± 1.4

0.146

 LVEF [%]

62 ± 8

61 ± 5

0.833

 Heart rate [BPM]

77 ± 9

79 ± 11

0.631

 SVES [n]/24 h

2 [0; 6]

4 [0; 52]

0.349

 VES [n]/24 h

8 [0; 37]

2 [0; 8]

0.197

 corrected QT interval [ms]

406 ± 20

403 ± 22

0.768

 QT dispersion [ms]

45 ± 18

44 ± 17

0.899

  1. Continuous variables are presented as mean ± standard deviation or median ± interquartile range as appropriate; categorial variables are presented as absolute numbers and percentage. p values in bold letters are significant. FCM ferric carboxymaltose, FDI ferric derisomaltose, eGFRCrea (CKD-EPI) estimated glomerular filtration rate (according to the CKD-EPI equation; “Chronic Kidney Disease Epidemiology Collaboration”), BMI body mass index, BP systolic systolic blood pressure, BP diastolic diastolic blood pressure, FGF23 fibroblast growth factor 23, FePi urinary fractional phosphorus excretion, LVMI left ventricular mass index, LAVI left atrial volume index, E/e’ diastolic left ventricular function, LVEF left ventricular ejection fraction, SVES supraventricular extrasystole, VES ventricular extrasystole
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us